160 related articles for article (PubMed ID: 38592002)
1. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Guarneri V; Passos Coelho JL; Duhoux FP; Egle D; García-Sáenz JÁ; Penault-Llorca F; Selander K; Wildiers H; Zaman K; Laeis P; Lucerna M; Pierga JY
Future Oncol; 2024 Apr; ():1-14. PubMed ID: 38592002
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
Modi S
Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
Yamashita T; Sohn JH; Tokunaga E; Niikura N; Park YH; Lee KS; Chae YS; Xu B; Wang X; Im SA; Li W; Lu YS; Aguilar CO; Nishijima S; Nishiyama Y; Sugihara M; Modi S; Tsurutani J
Breast Cancer; 2024 Jun; ():. PubMed ID: 38884900
[TBL] [Abstract][Full Text] [Related]
4. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
5. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04.
Zhan M; Huang Z; Xu T; Xu X; Zheng H; Wu F
Front Public Health; 2023; 11():1049947. PubMed ID: 37457280
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
[No Abstract] [Full Text] [Related]
9. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A; Caputo R; Scagnoli S; Pisegna S; De Laurentiis M; Curigliano G; Lambertini M; Pantano F; Palazzo A; Paris I; Vernieri C; Tedesco B; Giampaglia M; Palleschi M; Ballatore Z; Alesini D; D'Auria G; Fabbri A; Rossi L; Verrazzo A; Scafetta R; Marinelli D; Sposetti C; Barberi V; Strigari L; Marchetti P; Santini D; Fabi A
Oncologist; 2024 Apr; 29(4):303-310. PubMed ID: 37995313
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer.
Yang J; Han J; Zeng N; Yan X
Ther Adv Med Oncol; 2023; 15():17588359231169983. PubMed ID: 37228255
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
Shi D; Liang X; Li Y; Chen L
PLoS One; 2023; 18(8):e0290507. PubMed ID: 37616309
[TBL] [Abstract][Full Text] [Related]
13. How I treat HER2-low advanced breast cancer.
Schlam I; Tolaney SM; Tarantino P
Breast; 2023 Feb; 67():116-123. PubMed ID: 36669993
[TBL] [Abstract][Full Text] [Related]
14. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan.
Bardia A; Harnden K; Mauro L; Pennisi A; Armitage M; Soliman H
Oncologist; 2022 Aug; 27(8):637-645. PubMed ID: 35642907
[TBL] [Abstract][Full Text] [Related]
15. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.
Curigliano G; Dent R; Earle H; Modi S; Tarantino P; Viale G; Tolaney SM
ESMO Open; 2024 Apr; 9(4):102989. PubMed ID: 38613914
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT
BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab deruxtecan
Zhu Y; Liu K; Zhu X; Qin Q; Zhu H
Front Pharmacol; 2022; 13():1025243. PubMed ID: 36386213
[No Abstract] [Full Text] [Related]
[Next] [New Search]